Using Ibrutinib in Combination Therapies for CLL
Jennifer Woyach, MD, discusses the benefit of a combination therapy with ibrutinib for patients with chronic lymphocytic leukemia (CLL).
Watch
The Role of Oncology Nurse Navigators in Healthcare Reform
Carol Bush, BS, RN, discusses the role of oncology nurse navigators in healthcare reform.
Background of the Prophage G-200 Vaccine for Recurrent Glioblastoma Multiforme
Andrew T. Parsa MD, PhD, from the University of California, San Francisco, discusses the background of the prophage G-200 vaccine for recurrent glioblastoma multiforme.
The Approval of Revlimid for Patients with Relapsed or Refractory MCL
Andre Goy, MD, discusses the expanded approval of lenalidomide (Revlimid)for patients with relapsed or refractory mantle cell lymphoma (MCL)
The Grey Areas of Lung Cancer
Silvia Novello, MD, PhD, discusses some of the grey areas in lung cancer care.
On-Target and Off-Target Side Effects
Grace Dy, MD, Associate Professor, Department of Medicine, Roswell Park Cancer Institute, gives an overview of on-target and off-target side effects from anticancer targeted agents.
The Mechanism of Action of Ibrutinib
Craig L. Tendler, MD, discusses the mechanism of action of ibrutinib in various tumor types.
The Relationship Between CAR-Modified CD4 and CD8 T Cells in B-Cell Malignancies
Cameron J. Turtle, MD, PhD, discuses the relationship between CD4 and CD8 T cells in patients with B-cell malignancies.
The Difference Between the PAM50 Assay and Other Molecular Tests
Torsten O. Nielsen discusses the differences between the PAM50 assay and other approved molecular tests for patients with breast cancer.
The Challenges of GVHD in Patients with Lymphoma
Daniel H. Fowler, MD, discusses the challenges of graph-versus-host-disease (GVHD) in patients with high-risk lymphoma.
Ipilimumab 3 mg/kg vs 10 mg/kg in Metastatic Melanoma
Jeffrey A. Sosman, MD, from the Vanderbilt-Ingram Cancer Center, discusses a trial comparing two doses of ipilimumab for patients with metastatic melanoma.
The Side Effects of Lung Cancer Treatment
Bonnie Addario, a lung cancer survivor, discusses toxicities involved during lung cancer treatment.
Vinegar as a Screening Tool in the U.S.
Sandra Swain, MD, medical director of the Washington Cancer Institute at MedStar Washington Hospital Center, discusses the utility for vinegar as a screening tool in the U.S.
The Challenges of Treating Liver Cancer
Richard Finn, MD, from UCLA's Jonsson Comprehensive Cancer Center, discusses the difficulties of treating liver cancer.
Patient Response to Immunotherapy
Julie R. Brahmer, MD, Associate Professor, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses patient response to immunotherapy.
Effects of the Affordable Care Act
Ben Jones from McKesson Specialty Health discusses how the affordable care act will affect oncologists.
Sequencing and Combining Immunotherapies in Melanoma
Howard L. Kaufman, MD, says that the oncology community is in its infancy in terms of selecting and sequencing immunotherapies for patients with melanoma.
ALK inhibitors in Patients With NSCLC
Corey J. Langer, MD, from the Abramson Cancer Center, discusses recent advancements in treating an ALK mutation in patients with non-small cell lung cancer.
Surgery and Radiotherapy for Patients With Breast Cancer
Andrew D. Seidman, MD, from Memorial Sloan-Kettering Cancer Center, discusses breast cancer treatment with surgery and radiotherapy.
Afatinib in Patients With an EGFR Mutation
Giorgio V. Scagliotti, MD, PhD, from the University of Turin, San Luigi Hospital, Orbassano, Italy, discusses afatinib in patients with EGFR-mutated tumors.
T Cell Resistance to TGF-Beta in Lymphoma
Catherine Bollard, MBChB, MD, from the Baylor College of Medicine, discusses T cells and TGF-beta in Hodgkin's lymphoma and Non-Hodgkin lymphoma.
The Wnt Pathway and its Role in Colorectal Cancer
S. Gail Eckhardt, MD, Professor and Head of the Division of Medical Oncology at the University of Colorado Denver and Health Sciences Center, discusses the wnt pathway and its role in colorectal cancer.
Gene Assays and the Treatment of Breast Cancer
Kathy S. Albain, MD, from Loyola University Chicago, discusses gene assays as they relate to the treatment of patients with breast cancer.
PROFILE 1007 Trial: Crizotinib vs Pemetrexed or Docetaxel in NSCLC
D. Ross Camidge, MD, PhD, comments on the subgroup analysis of the PROFILE 1007 trial, which looked at crizotinib versus either pemetrexed or docetaxel in NSCLC.
Improving Lung Cancer Drug Development
Tony S.K. Mok, BMSc, MD, FRCPC, from the Prince of Wales Hospital Hong Kong, China, discusses how to improve the strategy of developing treatments for lung cancer.
Afatinib for Patients With EGFR Mutation
Paul A. Bunn, Jr, MD, from the University of Colorado, discusses afatinib for patients with activating epidermal growth factor receptor mutation.
PROSTVAC in Castration-Resistant Prostate Cancer
James L. Gulley, MD, PhD, discusses how PROSTVAC works in patients with castration-resistant prostate cancer.
Clincal Trial Endpoints in Ovarian Cancer
Carol Aghajanian, MD, from the Memorial Sloan-Kettering Cancer Center, discusses the difficulties with a gold standard clinical trial endpoint in ovarian cancer.
Advances in the Treatment of Lung Cancer
David P. Carbone, MD, PhD, from the The Ohio State University Wexner Medical Center, discusses advances in the treatment of lung cancer.
MEK Inhibitors for the Treatment of Melanoma
Alex A. Adjei, MD, PhD, discusses the use of MEK inhibitors when treating patients with melanoma.